News, Policy & Media

27Aug

New Chairman for MHRA

Stephen Lightfoot has been appointed as the Agency’s new Chair from 1st September 2020. He succeeds Prof Sir Michael Rawlins GBE, Kt who has been the Chair of the Agency Board since December 2014.

Stephen has been a Non-Executive Director of the Agency since September 2015 and is also Deputy Chair of Sussex Community NHS Foundation Trust and Non-Executive Chair of Sussex Primary Care Limited.

Before joining the Board, Stephen had a 30-year career in the life sciences industry working on the development and commercialisation of a wide range of medicines and medical devices in UK and global healthcare companies. His most recent executive roles were General Manager of the global pharmaceutical diagnostics business of GE Healthcare, Managing Director of the UK pharmaceutical business of Daiichi Sankyo and Commercial Director of the UK pharmaceutical and medical device business of Schering Healthcare.

BIVDA will be writing to Stephen when he takes up his position to outline the IVD sector's priorities for the MHRA, especially with regard to regulatory regimes post-December 31st when the transition period ends.

Related

NHS England has committed to the long term future of England’s Academic Health Science Networks (AH...

Read More >

UK-Japan Free Trade talks near completion   The UK-Japan Free Trade Agreement tra...

Read More >

Priti Patel has launched the UK's new points-based immigration system which will apply from 1 Ja...

Read More >

Government has said that it has reached its target of having a capacity to carry out 500,000 tests p...

Read More >

The UK IVD industry prepares for Brexit and new regulations.

Read More >

The importance of In-Vitro Diagnostics within healthcare will be discussed in a UK Summit to be held...

Read More >